Dawe R S, Crombie I K, Ferguson J
Photobiology Unit, Department of Dermatology, Ninewells Hospital and Medical School, Dundee, DD1 9SY, Scotland.
Arch Dermatol. 2000 Oct;136(10):1215-20. doi: 10.1001/archderm.136.10.1215.
To determine the prognosis for resolution of abnormal cutaneous photosensitivity in patients with chronic actinic dermatitis (also known as the photosensitivity dermatitis and actinic reticuloid syndrome).
Historical cohort study involving follow-up of patients for up to 24 years from diagnosis.
A Scottish tertiary referral center for investigation of photodermatosis.
One hundred seventy-eight patients with chronic actinic dermatitis, 62% of a cohort of 285 living patients identified in the Photobiology Unit database.
Recall for repeated clinical assessment and monochromator phototesting. All patients underwent patch testing when initially assessed; this was repeated at follow-up in a subgroup of patients.
Resolution of abnormal photosensitivity, defined as clinical resolution and return of phototest responses to within normal population limits. In addition, possible prognostic factors for resolution of photosensitivity were examined.
The probability of abnormal photosensitivity resolving by 10 years from diagnosis is 1 in 5. Particularly severe abnormal UV-B photosensitivity (minimal erythema dose at 305+/-5 nm half-maximum bandwidth, < or =5.6 mJ x cm(-2)) and the identification of separate contact allergens in 2 or more patch test batteries are predictors of a poorer prognosis for resolution. Loss of contact allergies was not associated with a different prognosis for photosensitivity resolution. Our findings probably underestimate the probability of resolution, as those referred to a tertiary referral center and willing to attend for follow-up may include a disproportionate number of severely affected patients.
Newly diagnosed patients can be told that most of them will improve with appropriate UV/visible light and allergen avoidance and that there is hope that their photosensitivity will completely resolve.
确定慢性光化性皮炎(也称为光敏性皮炎和光化性类网状细胞增多综合征)患者异常皮肤光敏性消退的预后情况。
一项历史性队列研究,对患者从诊断起进行长达24年的随访。
一家苏格兰三级转诊中心,用于光皮肤病的调查。
178例慢性光化性皮炎患者,占光生物学科数据库中确定的285例在世患者队列的62%。
召回患者进行重复临床评估和单色仪光测试。所有患者在初次评估时均接受斑贴试验;部分患者在随访时重复进行。
异常光敏性的消退,定义为临床消退且光测试反应恢复至正常人群范围内。此外,还研究了光敏性消退的可能预后因素。
从诊断起10年内异常光敏性消退的概率为五分之一。特别严重的异常UV-B光敏性(305±5nm半最大带宽处的最小红斑剂量,≤5.6mJ·cm⁻²)以及在2个或更多斑贴试验组中识别出单独的接触性变应原是消退预后较差的预测因素。接触性过敏的消失与光敏性消退的不同预后无关。我们的研究结果可能低估了消退的概率,因为转诊至三级转诊中心且愿意参加随访的患者中,严重受累患者的比例可能过高。
对于新诊断的患者,可以告知他们大多数人通过适当避免紫外线/可见光和变应原会有所改善,并且他们的光敏性有望完全消退。